Modeling the protein binding non-linearity in population pharmacokinetic model of valproic acid in children with

Lina Zhang1, Maochang Liu2, Weiwei Qin3

  • 1Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Frontiers in Pharmacology
|October 23, 2023
PubMed

Insights

Population pharmacokinetic models for valproic acid in children with epilepsy show poor predictive ability. The linear non-saturable binding equation and Bayesian forecasting with prior data improved model performance.

Area of Science:

  • Pharmacokinetics
  • Pediatric epilepsy
  • Drug metabolism

Background:

  • Population pharmacokinetics (popPK) models for valproic acid (VPA) in pediatric epilepsy are established.
  • The extrapolation and predictive performance of these models in diverse clinical settings remain unexamined.

Purpose of the Study:

  • To evaluate the predictive capabilities of existing pediatric VPA popPK models.
  • To assess the impact of different protein binding modeling strategies on VPA model performance.

Main Methods:

  • Analysis of 255 trough VPA concentrations from 202 pediatric epilepsy patients.
  • External validation using prediction diagnostics, simulation-based analysis, and Bayesian forecasting.
  • Development and comparison of five popPK models with varied protein binding strategies.

Main Results:

  • Ten VPA popPK models were identified; co-medication, body weight, dose, and age were key covariates for VPA clearance.
  • The Serrano et al. model demonstrated the best predictive performance among existing models.
  • All models showed inadequate simulation-based performance; the linear non-saturable binding equation and Bayesian forecasting improved predictability.

Conclusions:

  • Most VPA popPK models in pediatric epilepsy exhibit unsatisfactory predictive abilities.
  • The linear non-saturable binding equation is superior for modeling VPA's non-linear binding.
  • Bayesian forecasting enhances model accuracy, especially with sufficient prior data.

Related Concept Videos

Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding01:22

Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding

When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
190
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
49
Nonlinear Pharmacokinetics: Causes of Nonlinearity01:22

Nonlinear Pharmacokinetics: Causes of Nonlinearity

Nonlinearity in drug pharmacokinetics is caused by various factors influencing how a drug is absorbed, distributed, metabolized, and excreted. Understanding these nonlinear processes is crucial for predicting drug behavior in the body and optimizing drug dosing regimens.
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
206
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
733
Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
395
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
267